Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) Antibodies
(Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A))
This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene\; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012].
antibodies-online.com stands for high-quality research products. Search, find and order tools with extensive validation data, images, references. Our scientific customer service is always at your disposal if you have any questions about the selection or application of our products.
Featured Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) Categories
Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) Antibodies
High quality antibodies with extensive validation data.
Recommended Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) Antibodies
Product
Reactivity
Application
Validations
Cat. No.
Quantity
Datasheet
Reactivity
Human
Application
WB, IF, IHC (p), FACS
Validations
- (1)
- (5)
Cat. No.
ABIN1981278
Quantity
400 μL
Datasheet
Datasheet
Reactivity
Human
Application
WB, IF, IHC
Validations
- (4)
Cat. No.
ABIN6139280
Quantity
100 μL
Datasheet
Datasheet
Reactivity
Human
Application
WB, IHC (p)
Validations
- (1)
- (2)
Cat. No.
ABIN6241061
Quantity
400 μL
Datasheet
Datasheet
Latest Publications for our Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) products
: "Medroxyprogesterone Acetate Prevention of Cervical Cancer through Progesterone Receptor in a Human Papillomavirus Transgenic Mouse Model." in: The American journal of pathology, Vol. 189, Issue 12, pp. 2459-2468, (2020) (PubMed).: "Ezh2 programs TFH differentiation by integrating phosphorylation-dependent activation of Bcl6 and polycomb-dependent repression of p19Arf." in: Nature communications, Vol. 9, Issue 1, pp. 5452, (2019) (PubMed).
: "Canonical PRC2 function is essential for mammary gland development and affects chromatin compaction in mammary organoids." in: PLoS biology, Vol. 16, Issue 8, pp. e2004986, (2019) (PubMed).
: "p16Ink4a deletion in cells of the intervertebral disc affects their matrix homeostasis and senescence associated secretory phenotype without altering onset of senescence." in: Matrix biology : journal of the International Society for Matrix Biology, (2019) (PubMed).
: "CTGF Attenuates Tendon-Derived Stem/Progenitor Cell Aging." in: Stem cells international, Vol. 2019, pp. 6257537, (2019) (PubMed).
: "Resveratrol promotes oxidative stress to drive DLC1 mediated cellular senescence in cancer cells." in: Experimental cell research, Vol. 370, Issue 2, pp. 292-302, (2018) (PubMed).
: "Brain lipid-binding protein promotes proliferation and modulates cell cycle in C6 rat glioma cells." in: International journal of oncology, Vol. 51, Issue 5, pp. 1439-1448, (2018) (PubMed).
: "Cell-nonautonomous local and systemic responses to cell arrest enable long-bone catch-up growth in developing mice." in: PLoS biology, Vol. 16, Issue 6, pp. e2005086, (2018) (PubMed).
: "Loss of the clock gene PER2 is associated with cancer development and altered expression of important tumor-related genes in oral cancer." in: International journal of oncology, Vol. 52, Issue 1, pp. 279-287, (2018) (PubMed).
: "Spermidine prevents high glucose-induced senescence in HT-22 cells by upregulation of CB1 receptor." in: Clinical and experimental pharmacology & physiology, Vol. 45, Issue 8, pp. 832-840, (2018) (PubMed).
Synonyms and alternative names related to Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4)
cyclin dependent kinase inhibitor 2A (CDKN2A), cyclin-dependent kinase inhibitor 2A (Cdkn2a), cyclin-dependent kinase inhibitor 2A (LOC100340625), cyclin-dependent kinase inhibitor 2A (LOC100731972), ADP ribosylation factor-like 2 (Arl2), P14ARF (), ARF, Arf, ARF-INK4a, Arf84D, Arf84F, ARL2, arl2, Arl84F, CDK4I, CDKN2, CDKN2A, CG 7435, CG7435, CMM2, Dm Arf84F, Dmel\CG7435, INK4, INK4A, INK4a, INK4a-ARF, Ink4a/Arf, MLM, MTS-1, MTS1, P14, P14ARF, p14ARF, P16, p16, p16(INK4a), P16-INK4A, p16Cdkn2a, P16INK4, P16INK4A, p16INK4a, p16INK4A, P19, p19Protein level used designations for Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4)
- CDK4 inhibitor p16-INK4
- cell cycle negative regulator beta
- cyclin-dependent kinase 4 inhibitor A
- cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)
- multiple tumor suppressor 1
- CDK4I
- cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4)
- cyclin-dependent kinase inhibitor 2A, isoforms 1/2
- cyclin-dependent kinase inhibitor protein
- mitochondrial smARF
- p16-INK4
- p16-INK4a
- Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4)
- cell cycle inhibitor
- cell cycle regulator
- cyclin-dependent kinase inhibitor 2a p16Ink4a
- cyclin-dependent kinase inhibitor 2a p19Arf
- ADP ribosylation factor 84F
- ADP ribosylation factor like-2
- Arl2-PA
- CG7435 gene product from transcript CG7435-RA
- CG7435-PA
- arflike-2
- cyclin-dependent kinase inhibitor 2A
- p16/INK4A cyclin-dependent kinase inhibitor
Did you look for something else?
You are here:
